Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 6, 2005 - Issue 13
Submit an article Journal homepage
50
Views
17
CrossRef citations to date
0
Altmetric
Review

Targeting the renin-angiotensin-aldosterone-system in atrial fibrillation: a shift from electrical to structural therapy?

Anirban Choudhury Haemostasis, Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham B18 7QH, UK. [email protected]
,
George I Varughese Haemostasis, Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham B18 7QH, UK. [email protected]
&
Gregory YH Lip Haemostasis, Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham B18 7QH, UK. [email protected]
Pages 2193-2207 | Published online: 12 Oct 2005

Bibliography

  • BAILY D, LEHMANN MH, SCHUMACJER DN et al.: Hospitalization from arrhythmias in the United States: importance of atrial fibrillation. J. Am. Coll. Cardiol (1992) 19:41A.
  • FREESTONE B, LIP GY: Epidemiology and costs of cardiac arrhythmias: In: Cardiac Arrhythmias: a Clinical Approach. GY Lip, J Godtfredsen (Eds), Mosby, Edinburgh, Scotland (2003):3–24.
  • •Recent overview of the epidemiology of AE
  • WATTIGNEY WA, MENASH GA, CROFT JB: Increasing trends in hospitalization for atrial fibrillation in the United States, 1985 through 1999: implications for primary prevention. Circulation (2003) 108:711–716.
  • BENJAMIN EJ, WOLF PA, D'AGOSTINO RB et aL: Impact of atrial fibrillation on the risk of death: the Framingham Study. Circulation (1998) 98:946–952.
  • CARLSSON J, MIKETIC S, WINDELER J et al; STAF Investigators: Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. I Am. Coll. Cardiol (2003) 41(10):1690–1696.
  • WYSE DG, WALDO AL, DIMARCO JP et al.: Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators: a comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl. I Med. (2002) 347(23):1825–1833.
  • •The largest trial comparing rate control versus rhythm control.
  • HOHNLOSER SH, KUCH KH, LILIENTHAN J: Rhythm or rate control in atrial fibrillation-Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet (2000) 356:1789–1794.
  • VAN GELDER IC, HAGENS VE, BOSKER HA et al: Race control versus electrical cardioversion for persistent atrial fibrillation study group. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl. J. Med. (2002) 347:1834–1840.
  • EPSTEIN AE, CORLEY SD, DIMARCO JP et al: NHBL AFFIRM Investigators: Relationship between sinus rhythm, treatment and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) study [abstract]. Circulation (2003) 108:IV–472.
  • OKCUN B, YIGIT Z, KUCUKOGLU MS et al.: Predictors for maintenance of sinus rhythm after cardioversion in patients with nonvalvular atrial fibrillation. Echocardiography (2002) 19(5):351–357.
  • MATTIOLI AV, CASTELLI A, ANDRIA A et al: Clinical and echocardiographic features influencing recovery of atrial function after cardioversion of atrial fibrillation. Am. J. Cardiol (1998) 82(11):1368–1371.
  • CHEN MC, CHANG JP, CHANG HW: Preoperative atrial size predicts the success of radiofrequency maze procedure for permanent atrial fibrillation in patients ndergoing concomitant valvular surgery. Chest (2004) 125(6):2129–2134.
  • HAISSAGUERRE M, JAIS P, SHAH DC et al.: Catheter ablation of chronic atrial fibrillation targeting the reinitiating triggers. Cardiovasc. Electrophysiol (2000) 11:2–10.
  • ORAL H, KNIGHT BP, TADA H et al: Pulmonary vein isolation for paroxysmal and persistent atrial fibrillation. Circulation (2002) 105:1077–1081.
  • KARCH MR, ZRENNER B, DEISENHOFER I et al.: Freedom from atrial tachyarrhythmias after catheter ablation of atrial fibrillation: a randomized comparison between 2 current ablation strategies. Circulation (2005) 111:2875–2880.
  • NADEMANEE K, MCKENZIE J, KOSAR E et al.: A new approach for catheter ablation of atrial fibrillation: mapping of the electrophysiological substrate. I Am. Coll. Cardiol (2004) 43:2044–2053.
  • DELANGEN CDJ, VAN DEN BERG MP, HAAKSMA J et al.: Autocorrelation of AA intervals in artificially induced atrial fibrillation in the porcine heart. In: Atrial Fibrillation. Mechanisms and Therapeutic Strategies. SB Olsson, MA Allessie, RW Campbell (Eds), Futura Publising Co., Armonk, NY, USA (1994):51–66.
  • WIJFFELS MC, KIRCHHOF CJ, DORLAND R et al: Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation (1995) 92:1954–1968.
  • KONINGS KT, KIRCHHOF CJ, SMEETS JR et al: High density mapping of electrically induced atrial fibrillation in humans. Circulation (1994) 89:1665–1680.
  • WALDO AL, MACLEAN WA, COOPER TB et al: The use of temporarily placed epicardial leads atrial wire electrodes for the diagnosis and treatment of cardiac arrhythmias following open heart surgery. I Thorac. Cardiovasc. &mg. (1978) 76:500–505.
  • WELLS LJ, KARP RB, KOUCHOUKOS NT et al: Catheterization of atrial fibrillation in man: studies following open heart surgery. Pacing Electrophysiol (1978) 1:426–438.
  • PANDOZI C, SANTINI M: Update on atrial remodeling owing to rate; does atrial fibrillation always beget atrial fibrillation? Eur. Heart J. (2001) 22:541–553.
  • LAI LP, SU MJ, LIN JL et al: Down-regulation of the sarcoplasmic reticular Ca 2' -ATPase mRNA of ryanodine receptor, calsequestrin and phosphorylation: an insight into the mechanism of atrial remodelling. J. Am. Coll. Cardiol (1999) 33:1231–1237.
  • MORILLO CA, KLEIN GJ, JONES DL et al: Chronic rapid atrial pacing: structural, functional and electrophysiological characteristics of a new model of sustained atrial fibrillation. Circulation (1995) 91:1588–1595.
  • SANFILIPPO AJ, ABASCAL VM, SHEHAN M et al.: Atrial enlargement as a consequence of atrial fibrillation. A prospective echocardiographic study. Circulation (1990) 82:792–797.
  • LLESSIE MA, BOYDEN PA, CAMM AJ et al: Pathophysiology and prevention of atrial fibrillation. Circulation (2001) 103:769–777.
  • REISINGER J, GATTERER E, HEINZE G et al: Prospective comparison of flecainide versus sotalol for immediate cardioversion of AF. Am. J. Cardiol (1998) 81:1450–1454.
  • BOTTO GL, POLITI A, BONINI W et al.: External cardioversion of atrial fibrillation: role of paddle position on technical efficiency and energy requirements. Heart (1999) 82:726–730.
  • TIELMAN RG, VAN GELDER IC, CRIJNS HJ et al.: Early recurrence of atrial fibrillation after electrical cardioversion: a result of atrial fibrillation-induced electrical remodeling of the atria?" Am. Coll. Cardiol (1998) 31:167–173.
  • TIELEMAN RG, DE LANGEN C, VAN GELDER IC et al: Verapamil reduces tachycardia-induced electrical remodeling of the atria. Circulation (1997) 95:1945–1953.
  • TIELEMAN RG, BLAAUW Y, VAN GELDER IC et al: Digoxin delays recovery from tachycardia-induced remodeling of the atria. Circulation (1999) 100:1836–1842.
  • DE SIMONE A, STABILE G, VITALE DFet al.: Pretreatment with verapamil in patients with persistent or chronic atrial fibrillation who went electrical cardioversion. J. Am. Coll. Cardiol (1999) 34:810–814.
  • BOTTO GL, BELOTTI G, CIRO A et al:Verapamil pretreatment before electrical cardioversion of persistent atrial fibrillation: the VERAF Study. Eur. Heart J. (2001) 22:239.
  • EVERETT TH, LI H, MANGRUM JM et al: Electrical, morphological, and ultrastructural remodeling and reverse remodeling in a canine model of chronic atrial fibrillation. Circulation (2000) 102(12):1454–1460.
  • YU WC, LEE SH, TAI CT et al: Reversalof atrial electrical remodeling following cardioversion of long-standing atrial fibrillation in marl. Cardiovasc. Res. (1999) 42(2):470–476.
  • NAKASHIMA H, KUMAGAI K, URATA H et al.: Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation (2000) 101:2612–2617.
  • SOLTI F, VECSEY T, KEKESI V et al: Theeffect of atrial dilatation on the genesis of atrial arrhythmias. Cardiovasc. Res. (1989) 23:882–886.
  • RAVELLI F, ALLESSIE M: Effects of atrial dilatation on refractory period and vulnerability to atrial fibrillation in the isolated Langendorff-perfused rabbit heart. Circulation (1997) 96:1686–1695.
  • PAGES G, LENORMAND P, LALLEMAIN G: Mitogen-activated protein kinases p42mapk and p44mapk are required for fibroblast proliferation. Proc. Natl Acad. Sci. USA (1993) 90:8319–8323.
  • BRILLA CG, ZHOU G, MATSUBARA L et al.: Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. Mol Cardiol (1994) 26:809–820.
  • ZOU Y, KOMURO I, YAMAZAKI T et al.: Cell type-specific angiotensin II-evoked signal transduction pathways: critical roles of Gbetagamma subunit, Src family, and Ras in cardiac fibroblasts. Circ. Res. (1998) 82:337–345.
  • KUMAGAI K, NAKASHIMA H, URATA H et al.: Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J. Am. Coll. Cardiol (2003) 41:2197–2204.
  • BRILLA CG, SCHEER C, RUPP H: Renin-angiotensin system and myocardial collagen matrix: modulation of cardiac fibroblast function by angiotensin II type 1 receptor antagonism. ./. Hypertens. Suppl (1997) 5(6):513–519.
  • SECCIA TM, BELLONI AS, KREUTZ R et al.: Cardiac fibrosis occurs early and involves endothelin and AT-1 receptors in hypertension due to endogenous angiotensin II. ./. Am. Coll. Cardiol (2003) 41(4):666–673.
  • BOLDT A, WETZEL U, WEIGL J et al: Expression of angiotensin II receptors in human left and right atrial tissue in atrial fibrillation with and without underlying mitral valve disease. J. Am. Coll. Cardiol (2003) 42(10):1785–1792.
  • GOETTE A, STAACK T, ROCKEN C et al.: Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J. Am. Coll. Cardiol (2000) 35:1669–1677.
  • GOETTE A, ARNDT M, ROCKEN C et al.: Regulation of angiotensin II receptor subtypes during atrial fibrillation in humans. Circulation (2000) 101:2678–2681.
  • LID, SHINAGAWA K, PANG L et al: Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation (2001) 104(20:2608–2614.
  • SHI Y, LI D, TARDIF JC et al: Enalapril effects on atrial remodeling and atrial fibrillation in experimental congestive heart failure. Cardiovasc. Res. (2002) 54(2):456–461.
  • DURSUNOGLU D, TANRI VERDI H, EVRENGUL H et al.: Angiotensin-converting enzyme plymorphism in Turkish male athletes: relationship to left ventricular mass and function. BE J. Cardiol (2005) 12:145.
  • GENSINI F, PADELETTI L, FATINI C et al.: Angiotensin-converting enzyme and endothelial nitric oxide synthase polymorphisms in patients with atrial fibrillation. Pacing Clin. Electrophysiol (2003) 26:295–298.
  • DEVEREUX RB, DAHLOF B, GERDTS E et al: Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation (2004) 110(10:1456–1462.
  • DAHLOF B: Angiotensin-converting enzyme inhibitors and effects on left ventricular hypertrophy. Blood Press. Suppl (1994) 2:35–40.
  • THURMANN PA, KENEDI P, SCHMIDT A et al: Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. Circulation (1998) 98(19):2037–2042.
  • SCHNEIDER MP, KLINGBEIL AU, DELLES C et al: Effect of irbesartan versus atenolol on left ventricular mass and voltage: results of the CardioVascular Irbesartan Project. Hypertension (2004) 44(0:61–66.
  • DE LUCA N, MALLION JM, O'ROURKE MF et al.: Regression of left ventricular mass in hypertensive patients treated with perindopriVindapamide as a first-line combination: the REASON echocardiography study. Am. J. Hypertens. (2004) 17(8):660–667.
  • GRASSI G, CATTANEO BM, SERAVALLE G et al.: Effects of chronic ACE inhibition on sympathetic nerve traffic and baroreflex control of circulation in heart failure. Circulation (1997) 96:1173–1179.
  • EVERT T: Captopril potentiates chronic baroreflex response to carotid stimuli in humans. Hypertension (1985) 7:602–606.
  • LA ROVERE MT, BIGGER JT, MARCUS FL et al: Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. ATRAMI investigators. Lancet (1998) 351:478–484.
  • CABALLERO R, DELPON E, VALENZUELA C et al: Losartan and its metabolite E3174 modify cardiac delayed rectifier K(') currents. Circulation (2000) 36:139–146.
  • CHOUDHURY A, LIP GY: Atrial fibrillation and the hypercoagulable state: from basic science to clinical practice. Pathophysiol Haemost. Thromb. (2003) 33(5–6)282–289.
  • LIP GY, HART RG, CONWAY DS: Antithrombotic therapy for atrial fibrillation: clinical aspects. Br. Med. J. (2002) 325:1022–1025.
  • BOOS CJ, LIP GY: Novel therapies for the prevention of stroke. Expert Opin. Investig. Drugs (2004) 13:1615–1630.
  • GRIENDLING KK, USHIO-FUKAI M: Reactive oxygen species as mediators of angiotensin II signaling. Regul Pept. (2000) 91:21–27.
  • GRUNFELD S, HAMILTON CA, MESAROS S et al.: Role of superoxide in the depressed nitric oxide production by the endothelium of genetically hypertensive rats. Hypertension (1995) 26:854–857.
  • FAKHOURI F, PLACIER S, ARDAILLOU R et al: Angiotensin II activates collagen type I gene in the renal cortex and aorta of transgenic mice through interaction with endothelin and TGF-beta. J. Am. Soc. Nephrol (2001) 12(12)2701–2710.
  • GOMEZ-GARRE D, RUIZ-ORTEGA M, ORTEGO M et al.: Effects and interactions of endothelin-1 and angiotensin II on matrix protein expression and synthesis and mesangial cell growth. Hypertension (1996) 27(4):885–892.
  • ZHAO Q, ISHIBASHI M, HIASA K et al: Essential role of vascular endothelial growth factor in angiotensin II-induced vascular inflammation and remodeling. Hypertension (2004) 44:264–270.
  • TAMARAT R, SILVESTRE JS, DURIE M et al: Angiotensin II angiogenic effect in vivo involves vascular endothelial growth factor- and inflammation-related pathways. Lab. Invest. (2002) 82:747–756.
  • TUMMALA PE, CHEN XL, SUNDELL CL et al.: Angiotensin II induces vascular cell adhesion molecule-1 expression in rat vasculature: potential link between the renin-angiotensin system and atherosclerosis. Circulation (1999) 100:1223–1229.
  • ALVAREZ A, CERDA-NICOLAS M, NAIM ABU NABAH Y et al: Direct evidence of leukocyte adhesion in arterioles by angiotensin II. Blood (2004) 104:402–408.
  • NERI SERNERI GG, BODDI M et al: Cardiac angiotensin II participates in coronary microvessel inflammation of unstable angina and strengthens the immunomediated component. Circ. Res. (2004) 94:1630–1637.
  • RUIZ-ORTEGA M, RUPEREZ M, LORENZO O et al: Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney. Kidney Int. Suppl. (2002) 82:12–22.
  • ISHIBASHI M, HIASA K, ZHAO Q et al: Critical role of monocyte chemoattractant protein-1 receptor CCR2 on monocytes in hypertension-induced vascular inflammation and remodeling. Circ. Res. (2004) 94:1203–1210.
  • OMURA T, YOSHIYAMA M, KIM S et al.: Involvement of apoptosis signal-regulating kinase-1 on angiotensin II-induced monocyte chemoattractant protein-1 expression. Arterioscler. Thromb. Vasc. Biol. (2004) 24:270–275.
  • KIARASH A, PAGANO PJ, TAYEH M et al.: Upregulated expression of rat heart intercellular adhesion molecule-1 in angiotensin II - but not phenylephrine-induced hypertension. Hypertension (2001) 37:58–65.
  • JIANG B, XU S, HOU X et al: Angiotensin II differentially regulates interleukin- 1-beta-inducible NO synthase (iNOS) and vascular cell adhesion molecule-1 (VCAM-1) expression: role of p38 MAPK.J. Biol. Chem. (2004) 279:20363–20368.
  • DAS UN: Is angiotensin-II an endogenouspro-inflammatory molecule? Med. Sci. Monit. (2005) 11:155–162.
  • SUZUKI Y, RUIZ-ORTEGA M, LORENZO O et al: Inflammation and angiotensin II. Intl Biochem. Cell Biol. (2003) 35:881–900.
  • VAUGHAN DE, LAZOS SA, TONG K: Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis. Clin. Invest. (1995) 95(3):995–1001.
  • RIDKER PM, GABOURY CL, CONLIN PR et al.: Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function. Circulation (1993) 87(6):1969–1973.
  • GOODFIELD NE, NEWBY DE, LUDLAM CA et al: Effects of acute angiotensin II type 1 receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic parameters in patients with heart failure. Circulation (1999) 99(23):2983–2985.
  • ERDEM Y, USALAN C, HAZNEDAROGLU IC et al: Effects of angiotensin converting enzyme and angiotensin II receptor inhibition on impaired fibrinolysis in systemic hypertension. Am. J. Hypertens. (1999) 12:1071–1076.
  • VAUGHAN DE, ROULEAU JL, RIDKER PM et al.: Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. HEART Study Investigators. Circulation (1997) 96(2):442–447.
  • MANCHINI GB: Long-term use of angiotensin-converting enzyme inhibitors to modify endothelial dysfunction: a review of clinical investigations. Clin. Invest. Med. (2000) 23(2):144–161.
  • QUASCHNING T, D'USCIO LV, SHAW S et al.: Vasopeptidase inhibition restores renovascular endothelial dysfunction in salt-induced hypertension. Am. Soc. Nephrol. (2001) 12(10:2280–2287.
  • GOTO K, FUJII K, ONAKA U et al: Angiotensin-converting enzyme inhibitor prevents age-related endothelial dysfunction. Hypertension (2000) 36(4):581–587.
  • QUASCHNING T, D'USCIO LV, SHAW S et al.: Vasopeptidase inhibition exhibits endothelial protection in salt-induced hypertension. Hypertension (2001) 37(4):1108–1113.
  • ANDERSON TJ, ELSTEIN E, HABER H et al.: Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study). I Am. Coll Cardiol. (2000) 35(1):60–66.
  • GOTO K, FUJII K, ONAKA U et al: Renin-angiotensin system blockade improves endothelial dysfunction in hypertension. Hypertension (2000) 36(4):575–580.
  • NIELSEN FS, ROSSING P, GALL MA et al.: Lisinopril improves endothelial dysfunction in hypertensive NIDDM subjects with diabetic nephropathy. Land. Clin. Lab. Invest. 1997; 57(5):427–434.
  • DREXLER H, KURZ S, JESERICH M et al.: Effect of chronic angiotensin-converting enzyme inhibition on endothelial function in patients with chronic heart failure. Am. I Cardiol. (1995) 76(15):13E-18E.
  • HORNIG B, ARAKAWA N, HAUSSMANN D et al: Differential effects of quinaprilat and enalaprilat on endothelial function of conduit arteries in patients with chronic heart failure. Circulation (1998) 98(25):2842–2848.
  • JAMES IM, DICKENSON EJ, BURGOYNE W et al: Treatment of hypertension with captopril: preservation of regional blood flow and reduced platelet aggregation. I Hum. Hypertens. (1988) 2(1):21–25.
  • SOMEYA N, MOROTOMI Y, KODAMA K et al.: Suppressive effect of captopril on platelet aggregation in essential hypertension. I Cardiovasc. Pharmacol. (1984) 6(5):840–843.
  • IAKOVLEV VM, SEMENKIN AA, IUDIN SM et al.: [Effect of enalapril maleate on vascular endothelial function and platelet-endothelial interactions in patients with essential hypertension]. 7er. Arkh. (2000) 72(1):40–44.
  • JIMENEZ AM, MONTON M, GARCIA R et al: Inhibition of platelet activation in stroke-prone spontaneously hypertensive rats: comparison of losartan, candesartan, and valsartan. I Cardiovasc. Pharmacol. (2001) 37(4):406–412.
  • LI P, FERRARIO CM, BROSNIHAN KB: Losartan inhibits thromboxane A2-induced platelet aggregation and vascular constriction in spontaneously hypertensive rats. I Cardiovasc. Pharmacol. (1998) 32 (2) :198–205.
  • LEVY PJ, YUNIS C, OWEN J et al: Inhibition of platelet aggregability by losartan in essential hypertension. Am. J. Cardiol. (2000) 86(11):1188–1192.
  • KALINOWSKI L, MATYS T, CHABIELSKA E et Angiotensin II AT1 receptor antagonists inhibit platelet adhesion and aggregation by nitric oxide release. Hypertension (2002) 40:521–527.
  • SCHIFFRIN EL, PARK JB, INTENGAN HD et al: Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation (2000) 101(14):1653–1659.
  • MAKRIS TK, STAVROULAKIS GA, KRESPI PG et al.: Fibrinolyticihemostatic variables in arterial hypertension: response to treatment with irbesartan or atenolol. Am. J. Hypertens. (2000) 13(7):783–788.
  • YUSUF S, SLEIGHT P, POGUE J et al: The Heart Outcomes Prevention Evaluation Study Investigators: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl. J. Med. (2000) 342(3):145–153.
  • PROGRESS COLLABORATIVE GROUP: Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet (2001) 358(9287):1033–1041.
  • DAHLOF B, DEVEREUX RB, KJELDSEN SE et al.: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet (2002) 359(9311):995–1003.
  • MADRID AH, PENG J, ZAMORA J et al: The role of angiotensin receptor blockers and/or angiotensin converting enzyme inhibitors in the prevention of atrial fibrillation in patients with cardiovascular diseases: meta-analysis of randomized controlled clinical trials. Pacing Clin. Electrophysiol (2004) 27:1405–1410.
  • YUSUF S: From the HOPE to the ONTARGET and TRANSCEND studies: challenging in improving prognosis. Am. .1 Cardiol. (2002) 89:18A–26A.
  • GOLDBERG RJ, SEELEY D, BECKER RC et al: Impact of atrial fibrillation on the in-hospital and long-term survival of patients with acute myocardial infarction. A community-wide perspective. Am. Heart J. (1990) 119:996–1001.
  • FLUCK DC, OLSEN E, PENTECOST BL et al.: Natural history and clinical significance of arrhythmias after acute cardiac infarction. BE Heart J. (1967) 29:170–189.
  • JEWITT DE, BALCON R, RAFTERY EB et al.: Incidence and management of supraventricular arrhythmias after acute myocardial infarction. Lancet (1967) 2:734–738.
  • JULIAN DG, VALENTINE PA, MILLER GG: Disturbances of rate, rhythm and conduction in acute myocardial infarction. Am. J. Med. (1964) 37:915–927.
  • CRISTAL N, SZWARBERG J, GUERON M: Supraventricular arrhythmias in acute myocardial infarction. Prognostic importance of clinical setting; mechanism of production. Ann. Intern. Med. (1975) 82:35–39.
  • HELMERS C, LUNDMAN T, MOGENSEN L et al.: Atrial fibrillation in acute myocardial infarction. Acta. Med. Scand. (1973) 193:39–44.
  • KLASS M, HAYWOOD LJ: Atrial fibrillation associated with acute myocardial infarction. A study of 34 cases. Am. Heart J. (1970) 79:752–760.
  • LURIA MH, KNOKE JD, WACHS JS et al.: Survival after recovery from acute myocardial infarction. Two and five year prognostic indices. Am. J. Med. (1979) 67:7–14.
  • PEDERSEN OD, BAGGER H, KOBER L et al.: The occurrence and prognostic significance of atrial fibrillationi-flutter following acute myocardial infarction. Eur. Heart J. (1999) 20:748–754.
  • PEDERSEN OD, BAGGER H, KOBER L et al.: Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation (1999) 100:376–380.
  • MIDDLEKAUFF HR, STEVENSON WG, STEVENSON LW: Prognostic significance of atrial fibrillation in advanced heart failure. A study of 390 patients. Circulation (1991) 84(1):40–48.
  • SENNI M, TRIBOUILLOY CM, RODEHEFFER RJ et al.: Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation (1998) 98:2282–2289.
  • DEEDWANIA PC, SINGH BN, ELLENBOGEN K et al: Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the veterans affairs Congestive Heart Failure Survival Trial of Antiarrhythmic Therapy (CHF-STAT). The Department of Veterans Affairs CHF-STAT Investigators. Circulation (1998) 98:2574–2579.
  • WANG TJ, LARSON MG, LEVY D et al: Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality. The Framingham Heart Study. Circulation (2003) 107:2920–2925.
  • VERNES E, TARDIFF JC, BOURASSA MG et al.: Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction insight from the studies of left ventricular dysfunction (SOLVD) Trials. Circulation (2003) 107:2926–2931.
  • MAGGIONI AP, CARSON PE, SINGH SN et al: Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am. Heart J. (2005) 149:548–557.
  • HUNSICKER LG, ATKINS RC, LEWIS JB et al: Impact of irbesartan, blood pressure control, and proteinuria on renal outcomes in the Irbesartan Diabetic Nephropathy Trial. Kidney Int. Suppl. (2004) 92:S99–S101.
  • BAKRIS GL, WEIR MR, SHANIFAR S et al: Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch. Intern. Med. (2003) 163(13):1555–1565.
  • PSATY BM, MANOLIO TA, KULLER LH et al: Incidence of and risk factors for atrial fibrillation in older adults. Circulation (1997) 96:2455–2461.
  • KANNEL WB, WOLF PA, BENJAMIN EJ et al: Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am. J. Cardiol. (1998) 82:2N–9N.
  • CHUGH SS, BLACKSHEAR JL, SHEN WK et al.: Epidemiology and natural history of atrial fibrillation: clinical implications. J. Am. Coll Cardiol. (2001) 37:371–378.
  • KRAHN AD, MANFREDA J, TATE RB et al.: The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba follow-up study. Am. J. Med. (1995) 98:476–484.
  • WHELTON PK: Epidemiology of hypertension. Lancet (1994) 344:101–106.
  • LALLIER PL, DUCHARME A, KELLER P et al: Angiotensin-converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fibrillation. J. Am. Coll Cardiol. (2004) 44:159–164.
  • SIEGEL D, LOPEZ J: Trends in antihypertensive drug use in the United States: do the JNC V recommendations affect prescribing? Fifth Joint National Commission on the Detection, Evaluation, and Treatment of High Blood Pressure. JAMA (1997) 278:1745–1748.
  • WACHTELL K, LEHTO M, GERDTS E et al.: Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention for End Point Reduction in Hypertension (LIFE) Study. J. Am. Coll. Cardiol. (2005) 45:712–719.
  • •Important analysis from a large trial of ARBs in relation to AE
  • WACHTELL K, HORNESTAM B, LEHTO M et al: Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation. The Losartan Intervention for End Point Reduction in Hypertension (LIFE) Study. J. Am. Coll. Cardiol. (2005) 45:705–711.
  • •Important analysis from a large trial of ARBs in relation AE
  • MCFARLANE SI, SICA DA, SOWERS JR: Stroke in patients with diabetes and hypertension. J. Clin. Hypertens. (2005) 7(5):286–292.
  • FERRO JM: Atrial fibrillation and cardioembolic stroke. Minerva. Cardioangiol (2004) 52(2):111–124.
  • KANNEL WB, ABBOTT RD, SAVAGE DD et al: Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl. J. Med. (1982) 306(17):1018–1022.
  • BENJAMIN EJ, LEVY D, VAZIRI SM et al.: Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA (1994) 271(11):840–844.
  • POTPARA T, MARINKOVIC-ERIC J, GRUJIC Metal.: Effect of diabetes mellitus in recovery and maintenance of sinus rhythm in patients with persistent atrial fibrillation. Sip. Arh. Celok. Lek. (2002) 130:189–192.
  • SOWERS JR, STUMP CS: Insights into the biology of diabetic vascular disease: what's new? Am. Hypertens. (2004) 17S: 2–6
  • PARADIS P, DALI-YOUCEF N, PARADIS FW et al: Over expression of angiotensin II type I receptor in cardiomyocytes induces cardiac hypertrophy and remodeling. Proc. Nati Acad. Sci. (2000) 18:931–936.
  • DZAU VJ: Tissue renin-angiotensin system in myocardial hypertrophy and failure. Arch. Intern. Med. (1993) 153(8):937–942
  • LERI A, CLAUDIO PP, LI Q et al: Stretch-mediated release of angiotensin II induces myocyte apoptosis by activating p53 that enhances the local renin-angiotensin system and decreases the Bc1-2-to-Bax protein ratio in the cell. J. Clin. Invest. (1998) 101(7):1326–1342.
  • LERI A, FIORDALISP F, SETOGUCHI M et al.: Inhibition of p53 function prevents renin-angiotensin system activation and stretch-mediated myocyte apoptosis. Am. J. Pathol. (2000) 157(3):843–857.
  • CHOBANIAN AV, BAKRIS GL, BLACK HB et al.: Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension (2003) 42:1206–1252.
  • HIPPISLEY-COX J, PRINGLE M: Prevalence, care and outcomes for patients with diet-controlled diabetes in general practice: cross sectional survey. Lancet (2004) 363:423–428.
  • GUSTAFSSON I, BRENDORP B, SEIBAEK M et al.: Influence of diabetes and diabetes-gender interaction on the risk of death in patients hospitalized with congestive heart failure. J. Am. Coll. Cardiol. (2004) 43(5):771–777.
  • STRATTON IM, ADLER Al, NEIL HA et al: Association of glycaemia with macrovascular and microvascular complications of Type 2 diabetes (UKPDS 35): prospective observational study. Br. Med. J. (2000) 321:405–412.
  • REIS SE, HOLUBKOV R, EDMUNDOWICZ D et al: Treatment of patients admitted to the hospital with congestive heart failure: specialty-related disparities in practice patterns and outcomes. J. Am. Coll. Cardiol. (1997) 30:733–738.
  • SHINDLER DM, KOSTIS JB, YUSUF S et al: Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) trials and registry. Am. J. Cardiol (1996) 77:1017–1020.
  • MADRID AH, BUENO MG, REBOLLO JM et al.: Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation (2002) 106:331–336.
  • UENG KC, TSAI TP, YU WC et al: Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation: results of a prospective and controlled study. Eur. Heart J. (2003) 24:2090–2098.
  • SHINAGAWA K, MITAMURA H, OGAWA S et al.: Effects of inhibiting Nan/H(1-exchange or angiotensin converting enzyme on atrial tachycardia-induced remodeling. Cardiovasc. Res. (2002) 54(2):438–446.
  • FUKUMANI M, YAMADA T, OHMORI M et al: Detection of patients at risk for paroxysmal atrial fibrillation during sinus rhythm by P-wave triggered signal-averaged electrocardiogram. Circulation (1991) 83:162–169.
  • KUBARA I, IKEDA H, HIRAKI T et al: Dispersion of filtered P-wave duration by P-wave signal-averaged ECG mapping system: its usefulness for determining efficacy of disopyramide on paroxsy-mal atrial fibrillation. ./. Cardiovasc. Electrophysiol (1999) 10:670–679.
  • NATALE A, NEWBY KH, PISANO E et al.: Prospective randomized comparison of anti-arrhythmic therapy versus first-line radiofrequency ablation in patients with AFL. J. Am. Coll. Cardiol. (2000) 35:1898–904.
  • PHILIPPON F, PLUMB VJ, EPSTEIN AE et al.: The risk of AF following radiofrequency catheter ablation of AFL. Circulation (1995) 92:430–435.
  • SAXON LA, KALMAN JM, OLGIN JE et al.: Results of radiofrequency catheter ablation for AFL. Am. J. Cardiol. (1996) 77:1014–1016.
  • FREY B, KREINER G, BINDER T et al: Relation between left atrial size and secondary atrial arrhythmias after successful 2206 catheter ablation of common AFL. Pacing Clin. Electrophysiol (1997) 20:2936–2942.
  • TAI CT, CHEN SA, CHIANG CE et al: Long-term outcome of radiofrequency catheter ablation for typical AFL: risk prediction of recurrent arrhythmias. Cardiovasc. Electrophysiol (1998) 9:115–121.
  • REITHMANN C, HOFFMANN E, SPITZLBERGER G et al: Catheter ablation of AFL due to amiodarone therapy for paroxysmal AF. Eur. Heart J. (2000) 21:565–572.
  • NABAR A, RODRIGUEZ LM, TIMMERMANS C et al.: Effect of right atrial isthmus ablation on the occurrence of AF: observations in four patient groups having type I AFL with or without associated AF. Circulation (1999) 99:1441–1445.
  • PAYDAK H, KALL JG, BURKE MC et al: AF after radiofrequency ablation of type I AFL: time to onset, determinants, and clinical course. Circulation (1998) 98:315–322.
  • DA COSTA A, ROMEYER C, MOUROT S et al.: Factors associated with early AF after ablation of common AFL: a single centre prospective study. Eur. Heart J. (2002) 23:498–506.
  • ZAMAN AG, KEARNEY MT, SCHECTER C et al.: Angiotensin-converting enzyme inhibitors as adjunctive therapy in patients with persistent atrial fibrillation. Am. Heart J. (2004) 147:823–827.
  • ANNE W, WILLEMS R, MERWE N et al: Atrial fibrillation after radiofrequency ablation of atrial flutter: preventive effect of angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, and diuretics. Heart (2004) 90:1025–1030.
  • GOETTE A, LENDECKEL U, KLEIN HU: Signal transduction systems and atrial fibrillation. Cardiovasc. Res. (2002) 54:247–258.
  • SIU CW, LAU CP, TS HF: Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion. Am. J. Cardiol (2003) 92:1343–1345.
  • YOUNG-XU Y, JABBOUR S, GOLDBERG R et al: Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am. Cardiol (2003) 92:1379–1383.
  • TVEIT A, GRUNDTVIG M, GUNDERSEN T et al.: Analysis of pravastatin to prevent recurrence of atrial fibrillation after electrical cardioversion. Am. J. Cardiol (2004) 93:780–782.
  • MOZAFFARIAN D, PSATY BM, RIMM EB et al: Fish intake and risk of incident atrial fibrillation. Circulation (2004) 110:368–373.
  • FROST L, VESTERGAARD P: n-3 Fatty acids consumed from fish and risk of atrial fibrillation or flutter: the Danish Diet, Cancer, and Health Study. Am. I Clia Nutr. (2005) 81:50–54.
  • DERNELLIS J, PANARETOU M: Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation. Eur. Heart J. (2004) 25:1100–1107.
  • •Interesting study suggesting that suppression of inflammation reduces AF recurrence.
  • NISHIMURA Y, ITO T, SAAVEDRA JM: Angiotensin II AT(1) blockade normalizes cerebrovascular autoregulation and reduces cerebral ischemia in spontaneously hypertensive rats. Stroke (2000) 31(10) :2478–2486.

Websites

  • http://www.dukecardiology.duke.edui clinicalTrialListasp?divisionID=39-28k Duke University Medical Centre Cardiology homepage.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.